Guiling Li
Impact in
- Oncology top 2%
- COVID-19 and healthcare impacts
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Oncology 19
- PARP inhibition in cancer therapy 7
- COVID-19 and healthcare impacts 5
- Cancer Immunotherapy and Biomarkers 3
-
- Endometrial and Cervical Cancer Treatments 9
- Co-authors
- Yeshan Chen (3 shared papers)Gang Wu (3 shared papers)Yulan Zeng (1 shared paper)Linli Shi (2 shared papers)Shuangbing Xu (1 shared paper)Yang Qin (1 shared paper)Hanmei Lou (2 shared papers)Yingqiu Song (4 shared papers)
- Journals
- Gynecologic Oncology (4 papers)Clinical Cancer Research (3 papers)JAMA Oncology (2 papers)Cancer Management and Research (1 paper)BMC Cancer (1 paper)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Guiling Li
31 papers receiving 2.2k citations
Guiling Li's Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 1.3k
- Infectious Diseases 690
- Obstetrics and Gynecology 59
- Internal Medicine 18
- Reproductive Medicine 58
Countries citing papers authored by Guiling Li
This map shows the geographic impact of Guiling Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guiling Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guiling Li more than expected).
Fields of papers citing papers by Guiling Li
This network shows the impact of papers produced by Guiling Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guiling Li. The network helps show where Guiling Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Guiling Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak Hit paper breakdown → | 2020 | 1222 |
| 2 | Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study Hit paper breakdown → | 2020 | 440 |
| 3 | 2023 | 115 | |
| 4 | 2020 | 62 | |
| 5 | 2024 | 45 | |
| 6 | 2022 | 39 | |
| 7 | 2014 | 31 | |
| 8 | 2021 | 31 | |
| 9 | 2021 | 28 | |
| 10 | 2024 | 27 | |
| 11 | 2022 | 24 | |
| 12 | 2024 | 21 | |
| 13 | 2014 | 19 | |
| 14 | 2004 | 18 | |
| 15 | 2020 | 18 | |
| 16 | 2024 | 16 | |
| 17 | 2014 | 15 | |
| 18 | 2021 | 12 | |
| 19 | 2019 | 11 | |
| 20 | 2020 | 11 |
About Guiling Li
Guiling Li is a scholar working on Oncology, Obstetrics and Gynecology, Epidemiology, Reproductive Medicine and Infectious Diseases, having authored 33 papers that have together received 2.2k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (9 papers), PARP inhibition in cancer therapy (7 papers), COVID-19 and healthcare impacts (5 papers), Cervical Cancer and HPV Research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), COVID-19 Clinical Research Studies (2 papers), Neuroendocrine Tumor Research Advances (2 papers) and Ovarian cancer diagnosis and treatment (2 papers). The work is most often cited by research in Oncology (1.3k citations), Infectious Diseases (690 citations), Obstetrics and Gynecology (59 citations), Internal Medicine (18 citations) and Reproductive Medicine (58 citations). Guiling Li has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Yeshan Chen, Gang Wu, Yulan Zeng, Linli Shi, Shuangbing Xu, Yang Qin, Hanmei Lou, Yingqiu Song, Baiyong Li and Jing Wang. Their work appears in journals such as Gynecologic Oncology, Clinical Cancer Research, JAMA Oncology, Cancer Management and Research and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.